1. Cleanse the lesion site with saline and dab dry with sterile gauze.
2. Apply the medication on the lesion and adapt as needed.

Please, read the instructions and warnings for use carefully before using the device.

**AVAILABLE SIZES**

<table>
<thead>
<tr>
<th>Size</th>
<th>NTS-S</th>
<th>NTS</th>
<th>NTS-M</th>
<th>NTL-S</th>
<th>NTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pack</td>
<td>1 piece</td>
<td>6 pieces</td>
<td>1 piece</td>
<td>6 pieces</td>
<td>6 pieces</td>
</tr>
</tbody>
</table>

**Bibliography**

- Esposito C., et al., JLAST 2020; 4: 1-7

**Distributor in Spain:**

Moss S.p.A., Via d’Erno, 5 - 28040 Lesa (NO) - Italy
Tel: +39 0322 772032 - Fax: +39 0322 292733
moss@moss-brand.it - www.moss-brand.com

Calle Almendros 7: Paracuellos del Jarama
Madrid - 28860 - Spain
Silvia Nadelar - +34 609 25 90 98 - Silvia@leadingmedics.com
info@leadingmedics.com - www.leadingmedics.com
Class IIb medical device, specifically developed and manufactured in the form of a single-use tubular fingerstall or toecap for the treatment of finger and toe injuries. Dressing internally coated with an oleic matrix-based gel releasing Reactive Oxygen Species (ROS).

**INDICATIONS**
1. Diabetic ulcers
2. Finger and toe injuries
3. Traumatic wounds
4. Post-surgical wounds
5. Hypertrophic scars
6. Superficial burns

**ADVANTAGES**
1. Free from active pharmaceutical ingredients (APIs) and preservatives
2. Does not induce antibiotic resistance
3. Simplified application
4. Able to absorb small blood secretions and limited exudate quantities
5. Allows to inspect the wound bed
6. Can be cut out and shaped according to the required size
7. Can be modeled on the closed end, to preserve tactile sensitivity
8. Affords atraumatic removal

**MECHANISM OF ACTION**
1. **Novox®-Touch** has a film-forming action, opposing the contamination of lesions / wounds by pathogens.
2. **Novox®-Touch** facilitates the healing of surgical scars / chronic skin lesions, by promoting the activation of skin microcirculation.
3. **Novox®-Touch** has a soothing effect.
4. **Novox®-Touch** contributes to the stimulation of the granulation tissue and the re-epithelialization of acute and chronic lesions.

**TECHNOLOGY**
*Novox®-Touch* is based on a technological process studied and perfected by the R&D team of MOSS, which has maximized the enrichment of oxygen as part of an oleic matrix, so as to lend the medical device its technical features of constant, continuous release of ROS.